trending Market Intelligence /marketintelligence/en/news-insights/trending/mhoryanklri6h8qm0bjqtg2 content esgSubNav
In This List

PDL BioPharma elects director

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


PDL BioPharma elects director

PDL BioPharma Inc.'s stockholders elected Shlomo Yanai as a director at the 2018 annual meeting on June 8.

Yanai is currently serving as board chairman of Cambrex Corp. and Protalix BioTherapeutics Inc. He served as the president and CEO of Teva Pharmaceuticals Ltd. from 2007 to 2012, and then as an adviser until 2015.

Nevada-based PDL BioPharma acquires and manages companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries.